Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].

MLA

Garcia, Jacqueline S., et al. “Corrigendum to ‘A Systematic Review of Higher-Risk Myelodysplastic Syndromes Clinical Trials to Determine the Benchmark of Azacitidine and Explore Alternative Endpoints for Overall Survival’ [Leukemia Res. 104 March (2021)].” Leukemia Research, vol. 105, June 2021, p. 106581. EBSCOhost, https://doi.org/10.1016/j.leukres.2021.106581.

APA

Garcia, J. S., Swords, R. T., Roboz, G. J., Jacoby, M. A., Garcia-Manero, G., Hong, W.-J., Yang, X., Zhou, Y., Platzbecker, U., Steensma, D. P., Wolff, J. E., & Fenaux, P. (2021). Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” [Leukemia Res. 104 March (2021)]. Leukemia Research, 105, 106581. https://doi.org/10.1016/j.leukres.2021.106581

Chicago

Garcia, Jacqueline S, Ronan T Swords, Gail J Roboz, Meagan A Jacoby, Guillermo Garcia-Manero, Wan-Jen Hong, Xiaoqing Yang, et al. 2021. “Corrigendum to ‘A Systematic Review of Higher-Risk Myelodysplastic Syndromes Clinical Trials to Determine the Benchmark of Azacitidine and Explore Alternative Endpoints for Overall Survival’ [Leukemia Res. 104 March (2021)].” Leukemia Research 105 (June): 106581. doi:10.1016/j.leukres.2021.106581.